Cargando…
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
In the past decade, the development of immune checkpoint inhibitors in oncological clinical settings was in the forefront. However, the interest in musculoskeletal tumor patients as candidates for checkpoint inhibition remains underserved. Here, we are forwarding evidence proposing that galectin-3 (...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897198/ https://www.ncbi.nlm.nih.gov/pubmed/32929561 http://dx.doi.org/10.1007/s10555-020-09932-4 |